Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 9/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18540480 | 0.93 | MAPT (0.33) | GRK6CYP2C19MAPTALDH1A1PLA2G1B | |
| SCHEMBL18552240 | 0.89 | ALDH1A1 (0.36) | GRK6TYMPALDH1A1TDP1KMT2A | |
| SCHEMBL17212979 | 0.87 | TYMP (0.40) | GRK6TYMPCYP2C19MAPTALDH1A1 | |
| SCHEMBL17213041 | 0.85 | ALDH1A1 (0.34) | GRK6TYMPALDH1A1TDP1 | |
| SCHEMBL18540634 | 0.83 | TYMP (0.42) | GRK6TYMPCYP2C19MAPTALDH1A1 | |
| SCHEMBL18540633 | 0.81 | MEN1 (0.40) | GRK6TYMPCYP2C19MAPTALDH1A1 | |
| SCHEMBL17213141 | 0.80 | TYMP (0.38) | GRK6TYMPCYP2C19MAPTPLA2G1B | |
| SCHEMBL17213068 | 0.80 | TYMP (0.39) | GRK6TYMPMAPTALDH1A1PLA2G1B | |
| SCHEMBL18540629 | 0.80 | GRK6 (0.37) | GRK6TYMPCYP2C19MAPTALDH1A1 | |
| SCHEMBL17213136 | 0.80 | GRK6 (0.40) | GRK6TYMPCYP2C19MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050939-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2015164415-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050939-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | GRK6, GRK2, GRK3 | GRK6 1/4885TYMP 3730/4885CYP2C19 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.